ep-100
Peptideexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2009 (NCT00949559)
Timeline
Indications
Mechanism of action
- Progonadoliberin-1INHIBITOR
GNRH1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ep-100
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01485848 | Phase 2 | Feb 1, 2012 | Esperance Pharmaceuticals Inc |
| NCT00949559 | Phase 1 | Jul 1, 2009 | Esperance Pharmaceuticals Inc |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Esperance Pharmaceuticals Inc | For profit | 2 | 2 | 2 | 2009 |
1 organizations
Page 1 / 1